Johnson & Johnson (JNJ) Common Equity (2009 - 2026)

Johnson & Johnson's Common Equity history runs 18 years deep, the most recent figure standing at $81.2 billion for Q1 2026.

• In Q1 2026, Common Equity rose 3.94% year-over-year to $81.2 billion; the TTM figure through Mar 2026 stood at $81.2 billion (up 3.94% YoY), while the FY2025 annual figure was $81.5 billion, up 14.06% from the prior year.
• Common Equity came in at $81.2 billion for Q1 2026 at Johnson & Johnson, roughly flat from $81.5 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $81.5 billion in Q4 2025 to a low of $68.8 billion in Q4 2023.
• A 5-year average of $74.8 billion and a median of $74.7 billion in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity grew 16.98% in 2022 and slipped 10.46% in 2023, its largest moves.
• Johnson & Johnson's Common Equity stood at $74.6 billion in 2022, then retreated by 7.81% to $68.8 billion in 2023, then climbed by 3.95% to $71.5 billion in 2024, then climbed by 14.06% to $81.5 billion in 2025, then decreased by 0.44% to $81.2 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $81.2 billion, $81.5 billion, and $79.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison